155 related articles for article (PubMed ID: 6880748)
1. Impaired monocyte motility in sera from patients with systemic lupus erythematosus.
Sturfelt G; Linder C; Sjöholm AG; Svensson B
Acta Pathol Microbiol Immunol Scand C; 1983 Apr; 91(2):151-8. PubMed ID: 6880748
[TBL] [Abstract][Full Text] [Related]
2. Restoration of normal interactions between immune complexes and systemic lupus erythematosus blood cells by normal serum.
Medof ME; Oger JJ; Antel JP; Prince GM
J Clin Lab Immunol; 1982 Feb; 7(2):93-103. PubMed ID: 7069786
[TBL] [Abstract][Full Text] [Related]
3. Direct stimulation of neutrophil oxygenation activity by serum from patients with systemic lupus erythematosus: a relationship to disease activity.
Via CS; Allen RC; Welton RC
J Rheumatol; 1984 Dec; 11(6):745-53. PubMed ID: 6520828
[TBL] [Abstract][Full Text] [Related]
4. Monocyte in vitro function in systemic lupus erythematosus (SLE). II. Glass adherence and spreading in presence of SLE-sera.
Svensson B; Sturfelt G
Scand J Rheumatol Suppl; 1980; 31():43-52. PubMed ID: 6992267
[TBL] [Abstract][Full Text] [Related]
5. Expression of Fcgamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis.
Hepburn AL; Mason JC; Davies KA
Rheumatology (Oxford); 2004 May; 43(5):547-54. PubMed ID: 14747618
[TBL] [Abstract][Full Text] [Related]
6. Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.
Sakurai T; Fujita T; Kono I; Kabashima T; Yamane K; Tamura N; Kashiwagi H
Clin Exp Immunol; 1982 Apr; 48(1):37-42. PubMed ID: 6979449
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of monocyte reactive antibodies on monocyte chemotaxis in systemic lupus erythematosus.
Szegedi G; Lukács K; Bodolay E; Gulácsi L; Sonkoly I; Szabó G; Szöllösi J
Haematologia (Budap); 1985; 18(3):175-83. PubMed ID: 3836156
[TBL] [Abstract][Full Text] [Related]
8. Ability of complement to release systemic lupus erythematosus immune complexes from cell receptors.
Medof ME; Scarborough D; Miller G
Clin Exp Immunol; 1981 May; 44(2):416-25. PubMed ID: 7307341
[TBL] [Abstract][Full Text] [Related]
9. Monocyte in vitro function in systemic lupus erythematosus (SLE). I. A clinical and immunological study.
Svensson B
Scand J Rheumatol Suppl; 1980; 31():29-41. PubMed ID: 6992266
[TBL] [Abstract][Full Text] [Related]
10. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement.
Bijl M; Reefman E; Horst G; Limburg PC; Kallenberg CG
Ann Rheum Dis; 2006 Jan; 65(1):57-63. PubMed ID: 15919679
[TBL] [Abstract][Full Text] [Related]
11. A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus.
Perez HD; Lipton M; Goldstein IM
J Clin Invest; 1978 Jul; 62(1):29-38. PubMed ID: 659635
[TBL] [Abstract][Full Text] [Related]
12. Toxic effects of SLE serum on normal monocytes in vitro: cell death induced by apoptosis related to complement dysfunction.
Klint C; Truedsson L; Andreasson A; Johansson I; Sturfelt G
Lupus; 2000; 9(4):278-87. PubMed ID: 10866099
[TBL] [Abstract][Full Text] [Related]
13. Defective mononuclear phagocyte function in systemic lupus erythematosus: dissociation of Fc receptor-ligand binding and internalization.
Salmon JE; Kimberly RP; Gibofsky A; Fotino M
J Immunol; 1984 Nov; 133(5):2525-31. PubMed ID: 6481162
[TBL] [Abstract][Full Text] [Related]
14. Effect of autologous and homologous serum and circulating immune complexes on monocyte functions of patients with solid tumours.
Celada A; Aguado T; Lambert PH; Cruchaud A
Clin Exp Immunol; 1980 Aug; 41(2):326-35. PubMed ID: 7438558
[TBL] [Abstract][Full Text] [Related]
15. Monocyte in vitro function in systemic lupus erythematosus (SLE). III. Bactericidal activity in presence of SLE-sera.
Nived O; Odeberg H; Svensson B
Scand J Rheumatol Suppl; 1980; 31():53-5. PubMed ID: 6930101
[TBL] [Abstract][Full Text] [Related]
16. Evidence for intrinsic cellular defects of 'complement' receptor-mediated phagocytosis in patients with systemic lupus erythematosus (SLE).
Hurst NP; Nuki G; Wallington T
Clin Exp Immunol; 1984 Feb; 55(2):303-12. PubMed ID: 6697566
[TBL] [Abstract][Full Text] [Related]
17. Levels of complement in sera from inactive SLE patients, although decreased, do not influence in vitro uptake of apoptotic cells.
Grevink ME; Horst G; Limburg PC; Kallenberg CG; Bijl M
J Autoimmun; 2005 Jun; 24(4):329-36. PubMed ID: 15927794
[TBL] [Abstract][Full Text] [Related]
18. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus.
Ren Y; Tang J; Mok MY; Chan AW; Wu A; Lau CS
Arthritis Rheum; 2003 Oct; 48(10):2888-97. PubMed ID: 14558095
[TBL] [Abstract][Full Text] [Related]
19. Reduced complement-mediated immune complex solubilizing capacity and the presence of incompletely solubilized immune complexes in SLE sera.
Baatrup G; Petersen I; Jensenius JC; Svehag SE
Clin Exp Immunol; 1983 Nov; 54(2):439-47. PubMed ID: 6652967
[TBL] [Abstract][Full Text] [Related]
20. Solubilization of immune complexes and inhibition of immune precipitation in SLE sera.
Balestrieri G; Pagani D; Tincani A
J Clin Lab Immunol; 1983 Nov; 12(3):147-50. PubMed ID: 6663608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
